Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CHKA | P35790 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | DBH | P09172 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886163 | 0.88 | ESR1 (0.53) | LMNAESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL12658239 | 0.86 | LMNA (0.56) | LMNAMC4RALDH1A1KDM4EMAPT | |
| SCHEMBL3381044 | 0.86 | ESR1 (0.55) | ESR1ESR2ALDH1A1KDM4ENCF1 | |
| SCHEMBL4146260 | 0.85 | HRH3 (0.57) | ESR1ESR2ALDH1A1KDM4EHTT | |
| SCHEMBL14609609 | 0.84 | LMNA (0.58) | LMNAMC4RALDH1A1KDM4EMAPT | |
| SCHEMBL321512 | 0.82 | HRH3 (0.54) | ESR1ESR2MAPTNCF1HTT | |
| SCHEMBL15495062 | 0.82 | CHKA (0.58) | LMNAMC4RALDH1A1KDM4EMAPT | |
| SCHEMBL19111201 | 0.81 | LMNA (0.50) | LMNAMC4RALDH1A1KDM4EMAPT | |
| SCHEMBL16178546 | 0.80 | LMNA (0.62) | LMNAMC4RALDH1A1KDM4EMAPT | |
| SCHEMBL2927003 | 0.80 | LMNA (0.53) | LMNAMC4RALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103209979-B | therapeutic agent 976 | ASTRAZENECA AB (SE) | 2016-02-10 | — | — | CN | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| CN-103209979-A | Therapeutic agent 976 | ASTRAZENECA AB | 2013-07-17 | — | — | CN | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | LMNA 2005/4885ESR1 1380/4885ESR2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.